| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| DASL HiCaP | CTRIAL-IE 19-32 | Either very high-risk localised prostate cancer, or very high risk features with PSA persistence or rise within one year following radical prostatectomy, suitable for Radiotherapy. |
Determine the effectiveness of adding Darolutamide to androgen deprivation therapy (ADT) and radiation therapy in either the primary definitive setting or very high risk postoperative setting. |
DSSG Group: Genitourinary
PACE-C
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| PACE-C | CTRIAL-IE 15-46 | Intermediate/high risk prostate cancer |
The purpose of PACE-C is to determine whether prostate stereotactic body radiotherapy (SBRT) is non-inferior to conventional radiotherapy for freedom from biochemical/clinical failure in intermediate/high risk prostate cancer. |
IRONMAN: International Registry for Men with Advanced Prostate Cancer
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| IRONMAN: International Registry for Men with Advanced Prostate Cancer | CTRIAL-IE 17-30 | Metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC) |
The purpose of this study is to create an international, population-based, |
PEACE III
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| PEACE III | CTRIAL-IE 16-21 | asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone |
The purpose of this study is to find out whether the combination of Xofigo® (radium-223) and Xtandi® (enzalutamide) shows better activity against Xtandi® alone (enzalutamide) in metastatic prostate cancer and if the combination of Xofigo® (radium-223) and Xtandi® (enzalutamide) is safe. |